RBC Lifts Price Target on Spruce Biosciences to $9 From $8, Cites Improved Chances of Congenital Adrenal Hyperplasia Program Success; Outperform, Speculative Risk Kept
RBC Lifts Price Target on Spruce Biosciences to $9 From $8, Cites Improved Chances of Congenital Adrenal Hyperplasia Program Success; Outperform, Speculative Risk Kept
加拿大皇家銀行將Spruce Biosciences的目標股價從8美元上調至9美元，原因是先天性腎上腺增生計劃成功的機會增加；跑贏大盤，投機風險得以保持
Unity Software(U.US) reported fourth-quarter financial results after the market close on Monday. Here's a rundown of the report.Q4 Earnings: Unity said fourth-quarter revenue increased 35% year-over-year to $609 million, beating the consensus estimate of $562.71 million. The company reported a quarterly loss of 66 cents per share.
登入免費觀看全文
登入/註冊